Pharmafile Logo

Marathon Pharma

- PMLiVE

US cuts at Boehringer hit sales force hardest

And Arena Pharmaceuticals plans US and Swiss 'reductions'

- PMLiVE

Tracking comms trends: Europe in the global vanguard on value

From multi-disciplinary teamwork to pharma’s reputation, value and access to global briefs, our contributors tackle some of the key topics in communications today

China drug medicine pharma prices

Pfizer earmarks $350m for first Asian biotech facility

US pharma giant looks to tap into China’s pharmaceuticals market

- PMLiVE

Takeda hands back rights to two Amgen drugs

Returns pain and ovarian cancer candidates but will continue with collaboration

Celgene building

NICE rejects Celgene’s Vidaza for leukaemia

Final draft guidance cites ‘high degree of uncertainty’ over clinical efficacy

Celgene building

Celgene takes aim at cancer innovation with new US research consortium

Academic tie-up aims to develop new therapeutics and diagnostics

- PMLiVE

CDC says no to AZ’s intranasal flu vaccine FluMist

US government data reports “poor” efficacy for the injected vaccine alternative

Novartis Gehry Building

Heart failure drug Entresto ‘could save 28,000 lives a year’

New independent report looks set to boost sales of Novartis’ drug into blockbuster territory

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

- PMLiVE

Ariad files early marketing application for brigatinib

Second-line lung cancer therapy could be on the market by early 2017

- PMLiVE

SMC rejects Amgen’s Repatha over lack of outcomes data

But gives GlaxoSmithKline’s asthma drug Nucala the green light

- PMLiVE

Vertex’ cystic fibrosis drug too costly, says NICE

£104,000 per patient price tag is "too high" for the drug’s “modest” short term benefit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links